New military funding for Neuren's brain injury drug
This article was originally published in Scrip
Neuren Pharmaceuticals is to receive $5.5 million in new funding from the US military to support a planned Phase II trial with its neuroprotectant for traumatic brain injury (TBI) NNZ-2566.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.